LOADING

Chinese biotech aims $232M in IPO cash to push next-gen prostate cancer drug; Immunomedics raises nearly a half-billion off approval

A Chinese cancer-focused biotech looking to one-up J&J and Pfizer in castration-resistant prostate cancer has launched its IPO in Hong Kong, looking to raise more than $232 million (HK$1.86 billion) o..

More

Adaptive Biotech revenue rises 65% to $21M, loss widens amid big COVID-19 immune partnerships

Adaptive Biotechnologies, which is working with Microsoft and Amgen to fight COVID-19 using its technology for sequencing the human immune system, reported a 65% increase in first quarter revenue, to..

More

3 Biotech Stocks Under $3 With 200%-Plus Upside Potential

The healthcare sector took its place among the winners this year, rising 11%, compared to the S&P 500’s 9% drop. The bottom-line for investors? Wall Street’s focus is on the healthcare space, locking..

More

Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Development for COVID-19

Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, and Manhattan BioSolutions, Inc., a..

More
Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Development for COVID-19

Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, and Manhattan BioSolutions, Inc., a..

More
Dallas biotech Lantern Pharma looks to IPO to fund cancer drug development

Dallas-based biotech Lantern Pharma plans to raise $25 million through an initial public offering to fund development of its cancer drugs.  

More
Skyhawk's RNA Splicing Tech Draws in Expanded Merck Deal

Waltham, Massachusetts-based biotech company Skyhawk Therapeutics is expanding its strategic collaboration deal with Merck. The two companies are working to develop and commercialize a particular type..

More
Legend Biotech and Noile-Immune Biotech Announce Collaborative Research and Licensing ...

Legend Biotech Corporation (“Legend”), a global clinical stage biopharmaceutical company engaged in the discovery and development of novel cell therapies, announced today that Legend and Noile-Immune..

More